Skip to content

Supplement Compliance Risks: What Can Go Wrong

Last reviewed: April 1, 2026 | Next review: October 1, 2026

By Greg Huang, founder since 2009 in the dietary supplement and nutrition industry

Reviewed by Dr. James Pendleton, ND, licensed primary care physician, 20+ years in naturopathic medicine

No manufacturer will tell you about the things that go wrong. This guide covers real enforcement actions, the most common compliance failures, and what they cost. Understanding these risks is part of evaluating any manufacturing partner.

The short answer

FTC civil penalties can reach $53,088 per violation under Sections 5(l) and 5(m) of the FTC Act: order violations, knowing rule violations, and penalty offenses, with continuing violations accruing per day (2025 inflation-adjusted amounts, carried into 2026). The brand owner (whose name is on the label) typically faces the most direct consumer liability.

Dietary supplement manufacturers must comply with 21 CFR Part 111 (Current Good Manufacturing Practice for dietary supplements). This includes requirements for personnel, facilities, equipment, production, laboratory operations, and record-keeping.

Who Enforces Supplement Regulations

FDA (Food and Drug Administration)

Scope: Manufacturing compliance, cGMP, facility inspections, adulteration, misbranding, recalls

Enforcement power: Warning letters, import alerts, injunctions, seizures, criminal prosecution. These court-sought remedies can halt a facility's operations.

FTC (Federal Trade Commission)

Scope: Advertising and marketing claims, including social media, influencer content, and affiliate marketing. Any claim about what a supplement does must be truthful and substantiated. FTC and FDA coordinate under a formal liaison agreement and refer matters to each other; an advertising case can put a company on FDA's radar, though a referral does not automatically trigger facility inspections.

Enforcement power: Civil penalties up to $53,088 per violation under Sections 5(l) and 5(m) of the FTC Act (order violations, knowing rule violations, penalty offenses; 2025 amounts carried into 2026). Consent decrees, refund orders, and advertising bans.

State Attorneys General

Scope: Consumer protection, state-specific labeling requirements (California Prop 65), state advertising laws.

Enforcement power: Lawsuits, penalties, injunctions. Multi-state coordinated actions are increasingly common.

The Most Common Violations

FDA inspectionsof dietary supplement facilities result in Form 483 observations. These are the most frequently cited violations. If your manufacturer can't demonstrate compliance in these areas, that's a significant risk.

ViolationCFR ReferenceWhat It Means for You
No identity testing on incoming ingredients21 CFR 111.75(a)(1)You don't know what's actually in your product. Could be wrong ingredient, contaminated, or adulterated.
Incomplete batch production records21 CFR 111.255If a problem arises, there's no way to trace it. Recall becomes a guessing game.
No written procedures for quality control21 CFR 111.103Quality depends on whoever is working that day, not on consistent processes.
Releasing product without quality control approval21 CFR 111.123Quality control must approve and release each finished batch before distribution. Product that ships without that release can reach consumers before anyone confirms it meets specifications.
Inadequate equipment cleaning between products21 CFR 111.27Cross-contamination between products. Allergen risk. Potency problems.

Real Consequences: What Enforcement Looks Like

These are not hypothetical scenarios. They are categories of enforcement actions that happen regularly in the supplement industry.

Warning Letters

The FDA regularly issues warning letters to supplement companies for cGMP violations and unauthorized health claims. These are public documents. They appear in search results. Retailers check them. A warning letter on your manufacturer's record raises questions about every product they make.

Direct cost: $0 (it's a letter). Real cost: lost retailer relationships, consumer trust damage, and legal review expenses commonly in the $5,000 to $20,000+ range (IR editorial estimate, July 2026; not from a published survey).

Product Recalls

The FDA can request voluntary recalls or, in rare cases, mandate them. Common triggers: undeclared allergens, contamination with harmful substances, and products containing unapproved drug ingredients. The brand's name is on the recall notice, not the manufacturer's.

As an IR editorial estimate (July 2026, not from a published survey), recall costs typically range from $30,000 to $100,000 or more, though costs vary widely based on scope. Typical expenses include product retrieval, testing, consumer notification, legal fees, and lost inventory.

FTC Marketing Actions

The FTC targets deceptive advertising claims. "Boosts immunity," "burns fat," "prevents disease" without adequate scientific evidence are common triggers. In April 2023, the FTC issued Notices of Penalty Offenses to approximately 670 companies marketing health-related products including dietary supplements (FTC, April 13, 2023). Social media content and influencer marketing fall squarely within the FTC's Endorsement Guides (16 CFR Part 255, revised June 2023), and the FTC has brought health-claim actions over social and influencer content. The FTC and FDA coordinate enforcement under their liaison agreement, and FTC-FDA referrals mean a deceptive advertising case can escalate to manufacturing facility scrutiny. Influencer scripts, affiliate content, and user-generated testimonials that imply health benefits all carry the same liability as traditional advertising.

Civil penalties up to $53,088 per violation under Sections 5(l) and 5(m) of the FTC Act; in continuing-violation cases each day can count separately. First-instance deceptive-claim cases more often end in injunctions, consumer refunds, and advertising bans.

Prop 65 Lawsuits

California's Proposition 65 requires warnings for products that expose consumers to listed cancer- or reproductive-harm chemicals above the state's safe-harbor levels (containing a listed chemical below those levels does not by itself require a warning). Private plaintiffs (bounty hunters) can sue for violations. In 2025, Proposition 65 enforcement resulted in 293 in-court settlements totaling $19.85 million across all product categories according to California AG Proposition 65 annual settlement reports. Dietary supplements and food products have consistently accounted for roughly half of all Prop 65 enforcement actions according to Bureau Veritas Q1 2025 Prop 65 analysis. Supplement-specific settlement amounts are not reported separately.

Settlement: $25,000 to $100,000 or more per case according to California AG settlement reports and Spencer Fane's 2026 Prop 65 analysis. Legal defense: $15,000+. Ongoing testing to prevent recurrence: $2,000 to $5,000 per batch (source: industry laboratory pricing surveys).

How to Protect Your Brand

  • Check your manufacturer's FDA record before signing. Search the FDA warning letters database, request their most recent 483 observations, and ask for their corrective action responses.
  • Get a quality agreement separate from the manufacturing agreement. This document defines testing requirements, specification limits, deviation procedures, and dispute resolution. It should specify who bears the cost of failed batches.
  • Require third-party COAs for every batch. In-house testing is a start. Independent verification catches what in-house testing misses. This is your evidence if a problem arises.
  • Have your marketing claims reviewed by a regulatory attorney. Before you make any health-related claims. Not after you get the FTC letter. A review costs $2,000 to $5,000 (industry estimate, in line with published 2026 compliance-cost guides). An FTC action can cost $50,000+.
  • Carry product liability insurance. Minimum $1 million per occurrence, $2 million aggregate (source: industry-standard supplement policy minimums). Most retailers require this. Your manufacturer should carry their own policy as well.
  • Test for heavy metals if selling in California. Prop 65 lawsuits are a business risk. Proactive heavy metals testing is cheaper than reactive litigation.

Emerging Regulatory Trends (2026)

The regulatory landscape is shifting in several directions simultaneously. Brand owners should monitor these developments.

State Age Restrictions on Supplement Sales

New York is the only state to have enacted such a law (General Business Law Section 391-oo, effective April 22, 2024). Similar bills have been introduced in New Jersey, Michigan, Illinois, Massachusetts, Hawaii, and Rhode Island; California's bill was vetoed. A federal court declined to block the New York law, the Second Circuit affirmed that decision on November 13, 2025, and the Council for Responsible Nutrition has petitioned the U.S. Supreme Court, so the First Amendment challenge continues. Brands selling in these categories should prepare for state-by-state age verification at the point of sale.

THC Compliance Standards

Federal hemp standards enacted in November 2025 take effect November 12, 2026. Under Section 781 of H.R. 5371 (the fiscal 2026 appropriations law, enacted November 12, 2025), hemp is redefined by total THC: maximum 0.3% total THC by dry weight and 0.4 milligrams total THC per container for finished products. Section 781 also bars hemp-derived cannabinoid products from being labeled or marketed as dietary supplements or added to conventional foods once it takes effect. “Total THC” includes delta-9, THCA, and other cannabinoids with similar effects, not just delta-9 alone. Products exceeding these limits become controlled substances under federal law, risking enforcement action, product removal, and potential criminal penalties under the Controlled Substances Act. Bills to delay or amend the provision were introduced in 2026, but none had advanced out of committee as of mid-2026, and the deadline is expected to take effect as written. Brands using hemp-derived ingredients should verify total THC levels through third-party testing well before the November 2026 deadline.

Drug Preclusion and Ingredient Status

The FDA's drug preclusion doctrine prevents certain ingredients from being marketed as dietary supplements if they were first authorized for investigation or approved as drugs. On September 29, 2025, the FDA reversed its position on NMN (nicotinamide mononucleotide), confirming it is lawful in dietary supplements after determining that NMN was marketed as a supplement before it was authorized for drug investigation (FDA response to the NPA citizen petition, September 29, 2025; Venable LLP, October 2025). NMN remains classified as a New Dietary Ingredient, and companies must file a New Dietary Ingredient Notification (NDIN) with the FDA at least 75 days before marketing NMN products. CBD (cannabidiol) remains excluded under drug preclusion because it was authorized for investigation as a drug (Epidiolex) before being marketed as a supplement. In March 2026, FDA submitted a “CBD Products Compliance and Enforcement Policy” to the White House OIRA for review, and on April 1, 2026, FDA announced a narrow enforcement discretion policy covering only hemp-derived CBD products dispensed through Medicare programs under physician direction. No general policy for retail CBD supplements had been published as of July 2026. Brands should not formulate with CBD until the regulatory status is resolved. Ingredient regulatory status can change; verify current status before formulation and monitor FDA guidance.

Retailers as De Facto Regulators

Major retailers including Amazon and Walmart have established proprietary standards that go beyond FDA requirements: sustainable packaging, "clean" labeling, restricted ingredient lists, and mandatory third-party certifications. Compliance with FDA standards alone may no longer be sufficient for market access. Brands selling through major retail channels should track retailer-specific requirements alongside federal regulations.

Pressure-test your marketing claims

Claim language is the most common enforcement trigger discussed above. Our free substantiation checker flags claim phrasings that tend to draw FDA and FTC attention. Try the substantiation check →

Frequently Asked Questions

What happens if the FDA sends my manufacturer a warning letter?

An FDA warning letter means the agency found significant cGMP violations during inspection. FDA recommends that the manufacturer respond within 15 business days with a corrective action plan (this is guidance, not a statutory deadline, but failing to respond promptly increases the likelihood of further enforcement). If they don't fix the issues, FDA can pursue injunctions, seizures, or prosecution. As the brand owner, you need to assess whether your products were affected and whether to continue the manufacturing relationship.

Can the FTC fine me for supplement marketing claims?

Yes. Where specific authorities apply, FTC civil penalties can reach $53,088 per violation under Sections 5(l) and 5(m) of the FTC Act: violating an FTC order, knowingly violating an FTC rule, or the penalty-offense pathway. Continuing violations can accrue per day (source: FTC 2025 inflation-adjusted civil penalty amounts, carried into 2026 with no adjustment). First-instance deceptive-advertising cases more often end in injunctions, consumer refunds, and advertising bans. The FTC has been increasingly active in supplement enforcement, particularly around weight loss, immune support, and cognitive health claims.

Who is responsible if a supplement causes harm: the brand or the manufacturer?

Both can be held liable. The brand owner (whose name is on the label) typically faces the most direct consumer liability. The manufacturer can be liable under product liability law. Your manufacturing agreement should address indemnification and insurance requirements. Both parties should carry product liability insurance.

How do I check if my manufacturer has FDA violations?

Search the FDA's public databases: Warning Letters (fda.gov/inspections-compliance), Form 483 observations (via FOIA request), Import Alerts, and Recall databases. FDA facility registration records are confidential and not publicly searchable, so request registration confirmation directly from the facility. NSF and other third-party certifiers maintain their own compliance records.

Greg Huang, founder since 2009 in the dietary supplement and nutrition industry

Founder of Inventory Ready. Previously founded and operated multiple consumer brands in the dietary supplement and nutrition industry since summer 2009.

Concepts Covered

Stay informed

Regulatory updates, new manufacturer assessments, and tool launches. No spam.

Disclaimer: This guide is educational content, not legal or regulatory advice. Compliance requirements are complex and vary by product, ingredients, claims, and target markets. Consult with a qualified regulatory attorney and compliance professional before making decisions. See our Terms of Service for details.

Primary sources

The sourced claims in this guide are grounded in the following primary references. The guide's source manifest maps each claim to its source and verification date.

Find a Compliant Manufacturer

We assess manufacturers on cGMP compliance, certifications, and regulatory history. Tell us about your project.